Gyre Therapeutics | Evaluate

January 17, 2022

Groups slam Philip Morris, but the Vectura deal has precedent

No land grab for Gemini in geographic atrophy

Pivotal development of GEM103 is set to proceed, but the phase 2 result is a cautionary tale – not only for Gemini.

October 28, 2020

Another complement factor enters the deal-making frame

Sobi picking up rights to Apellis’s complement factor C3 inhibitor adds to earlier deals focused on C5, D and anti-FcRn antibodies.

November 04, 2009

EP Vantage Interview - Astra mixing it up and keeping deals flowing

October 20, 2009

Wye-Pfi R&D cull poses a threat to licensing deals